Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MINESH RAJPAL

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1568760502
CMS profile
1494173
Location
PEORIA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$143,288.70

177 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MINESH RAJPAL

NPI 1568760502 · CMS profile ID 1494173

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

PEORIA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568760502?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MINESH RAJPAL, NPI 1568760502, CMS profile ID 1494173. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568760502?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MINESH RAJPAL, NPI 1568760502, CMS profile ID 1494173. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568760502?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MINESH RAJPAL, NPI 1568760502, CMS profile ID 1494173, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1568760502?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

177 matching records · $143,288.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 177 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 177.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $109.9306/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062768 CMS
AstraZeneca Pharmaceuticals LP $45.6106/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105406231 CMS
AstraZeneca Pharmaceuticals LP $225.4406/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105577582 CMS
AstraZeneca Pharmaceuticals LP $177.2006/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105669365 CMS
AstraZeneca Pharmaceuticals LP $121.8406/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105807156 CMS
Otsuka America Pharmaceutical, Inc. $24.2206/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118966075 CMS
Bayer Healthcare Pharmaceuticals Inc. $6.6605/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086087441 CMS
Lilly USA, LLC $1,140.0005/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135209965 CMS
Amgen Inc. $2,700.0005/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117661597 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $3,125.0005/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062756 CMS
Bayer Healthcare Pharmaceuticals Inc. $3,413.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086171302 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,140.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062776 CMS
Lilly USA, LLC $1,140.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135207713 CMS
GlaxoSmithKline, LLC. $2,600.0005/06/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1155880433 CMS
Bayer Healthcare Pharmaceuticals Inc. $969.5205/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086078034 CMS
Bayer Healthcare Pharmaceuticals Inc. $7.7505/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086092103 CMS
Amgen Inc. $114.7705/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117661595 CMS
Bayer Healthcare Pharmaceuticals Inc. $121.8305/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086178140 CMS
AstraZeneca Pharmaceuticals LP $13.9004/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105494531 CMS
Lilly USA, LLC $1,140.0004/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135235813 CMS
AstraZeneca Pharmaceuticals LP $1,950.0004/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105550122 CMS
Bayer Healthcare Pharmaceuticals Inc. $2,888.0004/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086253532 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $42.6804/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062732 CMS
Bayer Healthcare Pharmaceuticals Inc. $120.8204/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086217947 CMS
AstraZeneca Pharmaceuticals LP $72.0004/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104702761 CMS
AstraZeneca Pharmaceuticals LP $125.2604/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105563854 CMS
Lilly USA, LLC $1,140.0004/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135173769 CMS
Bayer Healthcare Pharmaceuticals Inc. $1,838.0004/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086210841 CMS
AstraZeneca Pharmaceuticals LP $13.6604/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104659445 CMS
Travere Therapeutics, Inc. $28.8004/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149902302 CMS
Travere Therapeutics, Inc. $1,200.0004/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149902306 CMS
AstraZeneca Pharmaceuticals LP $2,450.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105705492 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $3,700.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062760 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,140.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062774 CMS
AstraZeneca Pharmaceuticals LP $36.1803/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104786208 CMS
AstraZeneca Pharmaceuticals LP $19.1903/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105464875 CMS
AstraZeneca Pharmaceuticals LP $2,450.0003/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104399137 CMS
Lilly USA, LLC $1,140.0003/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135256485 CMS
OPKO Pharmaceuticals, LLC $16.2103/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112848694 CMS
AstraZeneca Pharmaceuticals LP $16.5803/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105625855 CMS
Amgen Inc. $28.0903/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116039400 CMS
Lilly USA, LLC $1,140.0003/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135209961 CMS
AKEBIA THERAPEUTICS INC $2,550.0003/18/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145831943 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,140.0003/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062752 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,140.0003/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062754 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,140.0003/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062772 CMS
Lilly USA, LLC $1,140.0003/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135196174 CMS
Lilly USA, LLC $1,140.0003/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135196176 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $121.5003/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062738 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $821.2803/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118062746 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $143.57 8
PY2020 $96.00 5
PY2021 $334.83 18
PY2022 $62,139.76 144
PY2023 $97,185.09 158
PY2024 $143,288.70 177
PY2025 $99,774.26 182

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,115,863.03 47
PY2024 Principal investigator $905,172.25 34
PY2023 Principal investigator $169,987.90 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,967.04 12/18/2025 Non-covered Recipient Entity
Panoramic Science Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225415050
Principal investigator 1 Boehringer Ingelheim International GmbH $11,925.00 12/17/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220734145
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,217.04 12/01/2025 Non-covered Recipient Entity
Panoramic Science Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225415028
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,061.76 11/30/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220997380
Principal investigator 1 Boehringer Ingelheim International GmbH $39,050.00 11/17/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220734143
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,134.04 11/11/2025 Non-covered Recipient Entity
Panoramic Science Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225415366
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,061.76 10/31/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220997378
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,291.04 10/23/2025 Non-covered Recipient Entity
Panoramic Science Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225414134
Principal investigator 1 Boehringer Ingelheim International GmbH $25,580.00 10/22/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220734141
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $35,643.54 10/22/2025 Non-covered Recipient Entity
SOUTHWEST KIDNEY INSTITUTE SURPRISE
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy No dispute reported 06/30/2026 1214124954
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,061.76 09/30/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220997376
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,125.00 09/24/2025 Non-covered Recipient Entity
Clinical Renal Associates, Ltd
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $150.00 09/24/2025 Non-covered Recipient Entity
Clinical Renal Associates, Ltd
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519956
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,010.00 09/24/2025 Non-covered Recipient Entity
Clinical Renal Associates, Ltd
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519960
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $14,693.00 09/18/2025 Non-covered Recipient Entity
Panoramic Science Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225414604
Principal investigator 1 Boehringer Ingelheim International GmbH $18,890.00 09/08/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220734139
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 09/04/2025 Non-covered Recipient Entity
Panoramic Science Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225414602
Principal investigator 1 Eli Lilly and Company $168.00 09/04/2025 Non-covered Recipient Entity
SOUTHWEST KIDNEY INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187890916
Principal investigator 1 Boehringer Ingelheim International GmbH $21,705.00 08/18/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220734137
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,061.76 07/31/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220997374
Principal investigator 1 AstraZeneca Pharmaceuticals LP $226,149.11 07/23/2025 Non-covered Recipient Entity
PANORAMIC HEALTH
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185545439
Principal investigator 1 Boehringer Ingelheim International GmbH $25,355.00 07/07/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220734135
Principal investigator 1 Amgen Inc. $35,270.00 06/26/2025 Non-covered Recipient Entity
PANORAMIC SCIENCE LLC
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246646331
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,732.00 06/19/2025 Non-covered Recipient Entity
Panoramic Science Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412434
Principal investigator 1 Amgen Inc. $1,696.00 06/13/2025 Non-covered Recipient Entity
SOUTHWEST KIDNEY INSTITUTE, PLC
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246648506
Principal investigator 1 Boehringer Ingelheim International GmbH $13,080.00 06/09/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220734131
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,177.00 06/05/2025 Non-covered Recipient Entity
Panoramic Science Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412006
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $400.00 05/29/2025 Non-covered Recipient Entity
Panoramic Science Llc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412660
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,511.00 05/21/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225409146
Principal investigator 1 Boehringer Ingelheim International GmbH $16,350.00 05/12/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220734133
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $15,927.00 04/28/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225402623
Principal investigator 1 Boehringer Ingelheim International GmbH $9,810.00 04/09/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220734129
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $166.00 03/12/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225402645
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $80,123.52 02/28/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220997372
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,684.00 02/21/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225405970
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,228.00 02/19/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225404171
Principal investigator 1 Boehringer Ingelheim International GmbH $10,700.00 02/14/2025 Non-covered Recipient Entity
Panoramic Health
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220734127
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $360.00 02/07/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225403191
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,139.69 02/05/2025 Non-covered Recipient Entity
PANORAMIC HEALTH
A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension No dispute reported 06/30/2026 1185545441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $11,393.10 02/03/2025 Non-covered Recipient Entity
Clinical Renal Associates, Ltd
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519814
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $780.00 01/29/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411804
Principal investigator 1 Amgen Inc. $1,009,060.13 01/27/2025 Non-covered Recipient Entity
SOUTHWEST KIDNEY INSTITUTE
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246648511
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $600.00 01/24/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411776
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,500.00 01/13/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411764
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,970.00 01/08/2025 Non-covered Recipient Entity
Clinical Renal Associates, Ltd
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519778
Principal investigator 1 AstraZeneca Pharmaceuticals LP $237,235.92 01/03/2025 Non-covered Recipient Entity
PANORAMIC HEALTH
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185545435
Principal investigator 1 AstraZeneca Pharmaceuticals LP $53,169.82 01/03/2025 Non-covered Recipient Entity
PANORAMIC HEALTH
A Randomised Double-Blind Placebo-Controlled Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension No dispute reported 06/30/2026 1185545437